ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
Provided By GlobeNewswire
Last update: Dec 1, 2025
Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS’ PRECISE-AD trial
Read more at globenewswire.com9.1
+0.97 (+12%)
Find more stocks in the Stock Screener
PMN Latest News and Analysis
